Please login to the form below

Not currently logged in
Email:
Password:

RG3039

This page shows the latest RG3039 news and features for those working in and with pharma, biotech and healthcare.

Pfizer acquires spinal muscular atrophy research programme

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m. ... $5m. The main candidate involved in the programme is RG3039, which will undergo phase I trials carried out by Repligen in the first quarter of 2013.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    This programme includes RG3039, a small molecule drug candidate in clinical development, as well as backup compounds and enabling technologies. ... Licence. RG3039 orphan for spinal muscular atrophy. 70. Amplimmune / Daiichi Sankyo.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics